NEW YORK – After receiving 510 (k) clearance early this month from the US Food and Drug Administration for its sepsis test, Swiss diagnostics company Abionic is targeting the US for further ...

Last week, readers were most interested in a story about how priorities for the lab industry could play out depending on election results.

UK-based Cizzle Biotechnology signed the licensing agreement with its US-based partner, Cizzle Bio, for the commercialization of early cancer detection tests.

The automated real-time PCR-based test detects DNA from the virus that causes mpox using a dual-target approach and runs on Roche's high-throughput Cobas 6800/8800 systems. The EUL process is intended ...

The EU has awarded the researchers €188,000 to support the project through September 2026, by which time they hope to have a validated prototype ready.

Endometriosis is associated with debilitating pain and increased risk of cancer and autoimmune diseases, yet diagnosis remains out of reach for many patients.

The assay uses amplification-refractory mutation system (ARMS) technology and genetic analyzers to detect the 50 most common CF mutations in European ancestry populations.

In an open letter, the organization called on Danaher and its subsidiary Cepheid to further lower the price of its Xpert MTB/RIF Ultra tuberculosis test.

The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.

Aspira can now offer the test, intended for assessing ovarian cancer risk in women with an adnexal mass, to patients in New York state.